What To Expect From CME Group Stock?

+4.88%
Upside
213
Market
224
Trefis
CME: CME Group logo
CME
CME Group

CME Group’s stock (NYSE: CME) has gained 8% YTD, as compared to the 9% rise in the S&P500 over the same period. Further, at its current price of $182 per share, it is trading 12% below its fair value of $208 – Trefis’ estimate for CME Group’s valuationThe company outperformed the consensus estimates in the first quarter of 2023, with total revenues increasing by 7% y-o-y to $1.4 billion. It was primarily driven by a 5% improvement in clearing & transaction fees, followed by a 9% increase in market data & information services revenues. Notably, the clearing & transaction fees benefited from a 4% growth in the aggregate average daily volume (ADV), mainly driven by a 26% jump in the interest rates contracts. On the cost front, total expenses rose by 8% y-o-y, reducing the operating margin from 63.8% to 63.4%. However, the non-operating income increased from $57.2 million to $243.2 million, more than making up for higher expenses. Overall, the net income grew 24% y-o-y to $883.8 million.

The company’s top line grew 7% y-o-y to $5 billion in FY 2022, driven by a 10% improvement in clearing & transaction fees and a 6% increase in market data & information services revenues. The growth in clearing & transaction fees was driven by higher trading activity – aggregate ADV was up 19% y-o-y. That said, the non-operating income decreased from $728.4 million to $474.4 million in the year. It resulted in a net income of $2.7 billion – up 2% y-o-y.

Moving forward, we expect the higher trading volumes to continue in the subsequent quarters. Altogether, CME Group revenues are estimated to touch $5.36 billion in FY2023. Additionally, CME’s adjusted net income margin is likely to be around $3.1 billion in the year. This coupled with an annual EPS of $8.55 and a P/E multiple of just above 24x will lead to a valuation of $208.

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

 Returns May 2023
MTD [1]
2023
YTD [1]
2017-23
Total [2]
 CME Return -2% 8% 58%
 S&P 500 Return 1% 9% 87%
 Trefis Multi-Strategy Portfolio 0% 9% 244%
Relevant Articles
  1. Up 25% Since The Beginning of 2023, Where Is CME Group Stock Headed?
  2. Up 26% YTD, What’s Next For CME Group Stock?
  3. What To Expect From CME Group Stock?
  4. CME Group Stock To Top The Street Expectations In Q4
  5. What To Expect From CME Group Stock?
  6. CME Group Stock To Beat The Street Expectations In Q3?

[1] Month-to-date and year-to-date as of 5/22/2023
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates